Four integrated sites, 700+ scientists and engineers, and one quality system linking chemistry, biology, process development and manufacturing.
We've deliberately built the platform as modular and composable — you can engage with one piece or the whole pipeline.
Medicinal chemistry, biology, DMPK and in vivo pharmacology — target validation to lead candidate selection.
GLP toxicology, safety pharmacology and IND-enabling studies from our AAALAC-accredited facilities.
Route scouting, process optimisation, analytical method development, formulation and tech transfer.
cGMP API, biologics bulk drug substance, drug product and fill-finish — Phase I through commercial.
A 280-person integrated discovery team spanning chemistry, biology, DMPK and in vivo pharmacology. We support hit-to-lead, lead optimisation and candidate selection programs across oncology, immunology, metabolic disease, CNS and rare disease.
GLP-compliant toxicology, safety pharmacology and IND-enabling studies in AAALAC-accredited facilities. We have supported 62 IND packages including 28 US FDA and 14 EMA filings.
From grams to commercial scale — we develop, optimise and validate the processes that take your molecule through clinical supply and launch.
Inspection-ready cGMP manufacturing across small molecule API, biologics bulk drug substance, drug product and fill-finish — Phase I through commercial scale.
Our quality systems are built around FDA, EMA, PMDA and NMPA expectations. All sites are routinely audited by our customers and global regulators.
Share your target, molecule or program — our team will respond with a tailored proposal within days.
Request a Proposal